The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation
GOALS:To elucidate whether long-term supplementation with branched-chain amino acid (BCAA) granules improves overall survival (OS) and recurrence-free survival (RFS) after radiofrequency thermal ablation (RFA) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)≤3 cm in di...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical gastroenterology 2013-04, Vol.47 (4), p.359-366 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 366 |
|---|---|
| container_issue | 4 |
| container_start_page | 359 |
| container_title | Journal of clinical gastroenterology |
| container_volume | 47 |
| creator | Nishikawa, Hiroki Osaki, Yukio Iguchi, Eriko Koshikawa, Yorimitsu Ako, Soichiro Inuzuka, Tadashi Takeda, Haruhiko Nakajima, Jun Matsuda, Fumihiro Sakamoto, Azusa Henmi, Shinichiro Hatamaru, Keiichi Ishikawa, Tetsuro Saito, Sumio Nasu, Akihiro Kita, Ryuichi Kimura, Toru |
| description | GOALS:To elucidate whether long-term supplementation with branched-chain amino acid (BCAA) granules improves overall survival (OS) and recurrence-free survival (RFS) after radiofrequency thermal ablation (RFA) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of ≤3.5 g/dL.
BACKGROUND:Whether BCAA treatment after curative RFA for patients with HCV-related HCC improves OS and RFS remains unclear.
STUDY:We compared the OS rate and the RFS rate between the BCAA group (n=115) and the control group (n=141). We also examined factors contributing to OS and RFS.
RESULTS:The 1 and 3 years OS rates after RFA were 94.0% and 70.0%, respectively, in the BCAA group, and 94.0% and 49.8%, respectively, in the control group (P=0.001). The corresponding RFS rates 1 and 3 years after RFA were 61.8% and 28.0%, respectively, in the BCAA group, and 52.0% and 12.0%, respectively, in the control group (P=0.013). In the multivariate analysis, in terms of OS, BCAA treatment, and serum albumin level of ≥3.4 g/dL, and in terms of RFS, age 70 years or older, BCAA treatment, and a serum albumin level of ≥3.4 g/dL were significant independent factors, respectively.
CONCLUSIONS:BCAA treatment may improve OS and RFS after RFA in patients with HCV-related HCC≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of 3.5 g/dL. |
| doi_str_mv | 10.1097/MCG.0b013e31826be9ad |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1316377115</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1316377115</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356d-8a19e1b9a2a94794f6377ac0ea531d98c9166e81e0c34be87a4bdd185d1347c53</originalsourceid><addsrcrecordid>eNp9kc1u1TAQhSMEopfCGyDkJZsUT5w_L8NVuUW6CAQFltHEnhCDE6d2oqqPxtvhSwoLFqwse84588knSZ4DvwAuq1fv9ocL3nEQJKDOyo4k6gfJDgoh04wLeJjsOMgs5ZXkZ8mTEL5zDpUQ8Dg5ywSXnOdyl_y8Hohd9j2phbmeHd30LV3Ij-zTOs-WRpoWXIyb2FezDOy1x0kNpFM1oJlYM5rJsUYZzQ5xsloKLD5_iI7oC5vniuZ4X0xge_bF-DWkniwupLeJU2TtatGzPXoV80ZkTR8R2EfUxvWeblaa1B2LoH5Ey5rO_iZ6mjzq0QZ6dn-eJ5_fXF7vr9Lj-8PbfXNMlShKndYIkqCTmKHMK5n3pagqVJywEKBlrSSUJdVAXIm8o7rCvNMa6kKDyCtViPPk5ZY7exdRwtKOJpygcSK3hhYEnCIBTtJ8kyrvQvDUt7M3I_q7Fnh7Kq2NpbX_lhZtL-43rN1I-q_pT0tRUG-CW2fjz4Qfdr0l3w6Edhn-n_0LmiOpzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1316377115</pqid></control><display><type>article</type><title>The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Nishikawa, Hiroki ; Osaki, Yukio ; Iguchi, Eriko ; Koshikawa, Yorimitsu ; Ako, Soichiro ; Inuzuka, Tadashi ; Takeda, Haruhiko ; Nakajima, Jun ; Matsuda, Fumihiro ; Sakamoto, Azusa ; Henmi, Shinichiro ; Hatamaru, Keiichi ; Ishikawa, Tetsuro ; Saito, Sumio ; Nasu, Akihiro ; Kita, Ryuichi ; Kimura, Toru</creator><creatorcontrib>Nishikawa, Hiroki ; Osaki, Yukio ; Iguchi, Eriko ; Koshikawa, Yorimitsu ; Ako, Soichiro ; Inuzuka, Tadashi ; Takeda, Haruhiko ; Nakajima, Jun ; Matsuda, Fumihiro ; Sakamoto, Azusa ; Henmi, Shinichiro ; Hatamaru, Keiichi ; Ishikawa, Tetsuro ; Saito, Sumio ; Nasu, Akihiro ; Kita, Ryuichi ; Kimura, Toru</creatorcontrib><description>GOALS:To elucidate whether long-term supplementation with branched-chain amino acid (BCAA) granules improves overall survival (OS) and recurrence-free survival (RFS) after radiofrequency thermal ablation (RFA) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of ≤3.5 g/dL.
BACKGROUND:Whether BCAA treatment after curative RFA for patients with HCV-related HCC improves OS and RFS remains unclear.
STUDY:We compared the OS rate and the RFS rate between the BCAA group (n=115) and the control group (n=141). We also examined factors contributing to OS and RFS.
RESULTS:The 1 and 3 years OS rates after RFA were 94.0% and 70.0%, respectively, in the BCAA group, and 94.0% and 49.8%, respectively, in the control group (P=0.001). The corresponding RFS rates 1 and 3 years after RFA were 61.8% and 28.0%, respectively, in the BCAA group, and 52.0% and 12.0%, respectively, in the control group (P=0.013). In the multivariate analysis, in terms of OS, BCAA treatment, and serum albumin level of ≥3.4 g/dL, and in terms of RFS, age 70 years or older, BCAA treatment, and a serum albumin level of ≥3.4 g/dL were significant independent factors, respectively.
CONCLUSIONS:BCAA treatment may improve OS and RFS after RFA in patients with HCV-related HCC≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of 3.5 g/dL.</description><identifier>ISSN: 0192-0790</identifier><identifier>EISSN: 1539-2031</identifier><identifier>DOI: 10.1097/MCG.0b013e31826be9ad</identifier><identifier>PMID: 23090049</identifier><language>eng</language><publisher>United States: Lippincott Williams & Wilkins, Inc</publisher><subject>Age Factors ; Aged ; Amino Acids, Branched-Chain - administration & dosage ; Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - surgery ; Carcinoma, Hepatocellular - virology ; Catheter Ablation - adverse effects ; Catheter Ablation - mortality ; Chemistry, Pharmaceutical ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Hepatitis C - complications ; Hepatitis C - diagnosis ; Hepatitis C - mortality ; Humans ; Kaplan-Meier Estimate ; Liver Neoplasms - blood ; Liver Neoplasms - mortality ; Liver Neoplasms - pathology ; Liver Neoplasms - surgery ; Liver Neoplasms - virology ; Male ; Middle Aged ; Multivariate Analysis ; Neoplasm Recurrence, Local - prevention & control ; Neoplasm Recurrence, Local - virology ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Serum Albumin - metabolism ; Serum Albumin, Human ; Time Factors ; Treatment Outcome ; Tumor Burden</subject><ispartof>Journal of clinical gastroenterology, 2013-04, Vol.47 (4), p.359-366</ispartof><rights>2013 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356d-8a19e1b9a2a94794f6377ac0ea531d98c9166e81e0c34be87a4bdd185d1347c53</citedby><cites>FETCH-LOGICAL-c356d-8a19e1b9a2a94794f6377ac0ea531d98c9166e81e0c34be87a4bdd185d1347c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23090049$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishikawa, Hiroki</creatorcontrib><creatorcontrib>Osaki, Yukio</creatorcontrib><creatorcontrib>Iguchi, Eriko</creatorcontrib><creatorcontrib>Koshikawa, Yorimitsu</creatorcontrib><creatorcontrib>Ako, Soichiro</creatorcontrib><creatorcontrib>Inuzuka, Tadashi</creatorcontrib><creatorcontrib>Takeda, Haruhiko</creatorcontrib><creatorcontrib>Nakajima, Jun</creatorcontrib><creatorcontrib>Matsuda, Fumihiro</creatorcontrib><creatorcontrib>Sakamoto, Azusa</creatorcontrib><creatorcontrib>Henmi, Shinichiro</creatorcontrib><creatorcontrib>Hatamaru, Keiichi</creatorcontrib><creatorcontrib>Ishikawa, Tetsuro</creatorcontrib><creatorcontrib>Saito, Sumio</creatorcontrib><creatorcontrib>Nasu, Akihiro</creatorcontrib><creatorcontrib>Kita, Ryuichi</creatorcontrib><creatorcontrib>Kimura, Toru</creatorcontrib><title>The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation</title><title>Journal of clinical gastroenterology</title><addtitle>J Clin Gastroenterol</addtitle><description>GOALS:To elucidate whether long-term supplementation with branched-chain amino acid (BCAA) granules improves overall survival (OS) and recurrence-free survival (RFS) after radiofrequency thermal ablation (RFA) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of ≤3.5 g/dL.
BACKGROUND:Whether BCAA treatment after curative RFA for patients with HCV-related HCC improves OS and RFS remains unclear.
STUDY:We compared the OS rate and the RFS rate between the BCAA group (n=115) and the control group (n=141). We also examined factors contributing to OS and RFS.
RESULTS:The 1 and 3 years OS rates after RFA were 94.0% and 70.0%, respectively, in the BCAA group, and 94.0% and 49.8%, respectively, in the control group (P=0.001). The corresponding RFS rates 1 and 3 years after RFA were 61.8% and 28.0%, respectively, in the BCAA group, and 52.0% and 12.0%, respectively, in the control group (P=0.013). In the multivariate analysis, in terms of OS, BCAA treatment, and serum albumin level of ≥3.4 g/dL, and in terms of RFS, age 70 years or older, BCAA treatment, and a serum albumin level of ≥3.4 g/dL were significant independent factors, respectively.
CONCLUSIONS:BCAA treatment may improve OS and RFS after RFA in patients with HCV-related HCC≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of 3.5 g/dL.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Amino Acids, Branched-Chain - administration & dosage</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>Catheter Ablation - adverse effects</subject><subject>Catheter Ablation - mortality</subject><subject>Chemistry, Pharmaceutical</subject><subject>Disease-Free Survival</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C - diagnosis</subject><subject>Hepatitis C - mortality</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver Neoplasms - virology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Neoplasm Recurrence, Local - virology</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Risk Factors</subject><subject>Serum Albumin - metabolism</subject><subject>Serum Albumin, Human</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Tumor Burden</subject><issn>0192-0790</issn><issn>1539-2031</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc1u1TAQhSMEopfCGyDkJZsUT5w_L8NVuUW6CAQFltHEnhCDE6d2oqqPxtvhSwoLFqwse84588knSZ4DvwAuq1fv9ocL3nEQJKDOyo4k6gfJDgoh04wLeJjsOMgs5ZXkZ8mTEL5zDpUQ8Dg5ywSXnOdyl_y8Hohd9j2phbmeHd30LV3Ij-zTOs-WRpoWXIyb2FezDOy1x0kNpFM1oJlYM5rJsUYZzQ5xsloKLD5_iI7oC5vniuZ4X0xge_bF-DWkniwupLeJU2TtatGzPXoV80ZkTR8R2EfUxvWeblaa1B2LoH5Ey5rO_iZ6mjzq0QZ6dn-eJ5_fXF7vr9Lj-8PbfXNMlShKndYIkqCTmKHMK5n3pagqVJywEKBlrSSUJdVAXIm8o7rCvNMa6kKDyCtViPPk5ZY7exdRwtKOJpygcSK3hhYEnCIBTtJ8kyrvQvDUt7M3I_q7Fnh7Kq2NpbX_lhZtL-43rN1I-q_pT0tRUG-CW2fjz4Qfdr0l3w6Edhn-n_0LmiOpzw</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Nishikawa, Hiroki</creator><creator>Osaki, Yukio</creator><creator>Iguchi, Eriko</creator><creator>Koshikawa, Yorimitsu</creator><creator>Ako, Soichiro</creator><creator>Inuzuka, Tadashi</creator><creator>Takeda, Haruhiko</creator><creator>Nakajima, Jun</creator><creator>Matsuda, Fumihiro</creator><creator>Sakamoto, Azusa</creator><creator>Henmi, Shinichiro</creator><creator>Hatamaru, Keiichi</creator><creator>Ishikawa, Tetsuro</creator><creator>Saito, Sumio</creator><creator>Nasu, Akihiro</creator><creator>Kita, Ryuichi</creator><creator>Kimura, Toru</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation</title><author>Nishikawa, Hiroki ; Osaki, Yukio ; Iguchi, Eriko ; Koshikawa, Yorimitsu ; Ako, Soichiro ; Inuzuka, Tadashi ; Takeda, Haruhiko ; Nakajima, Jun ; Matsuda, Fumihiro ; Sakamoto, Azusa ; Henmi, Shinichiro ; Hatamaru, Keiichi ; Ishikawa, Tetsuro ; Saito, Sumio ; Nasu, Akihiro ; Kita, Ryuichi ; Kimura, Toru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356d-8a19e1b9a2a94794f6377ac0ea531d98c9166e81e0c34be87a4bdd185d1347c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Amino Acids, Branched-Chain - administration & dosage</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>Catheter Ablation - adverse effects</topic><topic>Catheter Ablation - mortality</topic><topic>Chemistry, Pharmaceutical</topic><topic>Disease-Free Survival</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C - diagnosis</topic><topic>Hepatitis C - mortality</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver Neoplasms - virology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Neoplasm Recurrence, Local - virology</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Risk Factors</topic><topic>Serum Albumin - metabolism</topic><topic>Serum Albumin, Human</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Tumor Burden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishikawa, Hiroki</creatorcontrib><creatorcontrib>Osaki, Yukio</creatorcontrib><creatorcontrib>Iguchi, Eriko</creatorcontrib><creatorcontrib>Koshikawa, Yorimitsu</creatorcontrib><creatorcontrib>Ako, Soichiro</creatorcontrib><creatorcontrib>Inuzuka, Tadashi</creatorcontrib><creatorcontrib>Takeda, Haruhiko</creatorcontrib><creatorcontrib>Nakajima, Jun</creatorcontrib><creatorcontrib>Matsuda, Fumihiro</creatorcontrib><creatorcontrib>Sakamoto, Azusa</creatorcontrib><creatorcontrib>Henmi, Shinichiro</creatorcontrib><creatorcontrib>Hatamaru, Keiichi</creatorcontrib><creatorcontrib>Ishikawa, Tetsuro</creatorcontrib><creatorcontrib>Saito, Sumio</creatorcontrib><creatorcontrib>Nasu, Akihiro</creatorcontrib><creatorcontrib>Kita, Ryuichi</creatorcontrib><creatorcontrib>Kimura, Toru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishikawa, Hiroki</au><au>Osaki, Yukio</au><au>Iguchi, Eriko</au><au>Koshikawa, Yorimitsu</au><au>Ako, Soichiro</au><au>Inuzuka, Tadashi</au><au>Takeda, Haruhiko</au><au>Nakajima, Jun</au><au>Matsuda, Fumihiro</au><au>Sakamoto, Azusa</au><au>Henmi, Shinichiro</au><au>Hatamaru, Keiichi</au><au>Ishikawa, Tetsuro</au><au>Saito, Sumio</au><au>Nasu, Akihiro</au><au>Kita, Ryuichi</au><au>Kimura, Toru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation</atitle><jtitle>Journal of clinical gastroenterology</jtitle><addtitle>J Clin Gastroenterol</addtitle><date>2013-04</date><risdate>2013</risdate><volume>47</volume><issue>4</issue><spage>359</spage><epage>366</epage><pages>359-366</pages><issn>0192-0790</issn><eissn>1539-2031</eissn><abstract>GOALS:To elucidate whether long-term supplementation with branched-chain amino acid (BCAA) granules improves overall survival (OS) and recurrence-free survival (RFS) after radiofrequency thermal ablation (RFA) in patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC)≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of ≤3.5 g/dL.
BACKGROUND:Whether BCAA treatment after curative RFA for patients with HCV-related HCC improves OS and RFS remains unclear.
STUDY:We compared the OS rate and the RFS rate between the BCAA group (n=115) and the control group (n=141). We also examined factors contributing to OS and RFS.
RESULTS:The 1 and 3 years OS rates after RFA were 94.0% and 70.0%, respectively, in the BCAA group, and 94.0% and 49.8%, respectively, in the control group (P=0.001). The corresponding RFS rates 1 and 3 years after RFA were 61.8% and 28.0%, respectively, in the BCAA group, and 52.0% and 12.0%, respectively, in the control group (P=0.013). In the multivariate analysis, in terms of OS, BCAA treatment, and serum albumin level of ≥3.4 g/dL, and in terms of RFS, age 70 years or older, BCAA treatment, and a serum albumin level of ≥3.4 g/dL were significant independent factors, respectively.
CONCLUSIONS:BCAA treatment may improve OS and RFS after RFA in patients with HCV-related HCC≤3 cm in diameter with up to 3 nodules and a serum albumin level before RFA of 3.5 g/dL.</abstract><cop>United States</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>23090049</pmid><doi>10.1097/MCG.0b013e31826be9ad</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0192-0790 |
| ispartof | Journal of clinical gastroenterology, 2013-04, Vol.47 (4), p.359-366 |
| issn | 0192-0790 1539-2031 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1316377115 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Age Factors Aged Amino Acids, Branched-Chain - administration & dosage Biomarkers, Tumor - blood Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Carcinoma, Hepatocellular - virology Catheter Ablation - adverse effects Catheter Ablation - mortality Chemistry, Pharmaceutical Disease-Free Survival Drug Administration Schedule Female Hepatitis C - complications Hepatitis C - diagnosis Hepatitis C - mortality Humans Kaplan-Meier Estimate Liver Neoplasms - blood Liver Neoplasms - mortality Liver Neoplasms - pathology Liver Neoplasms - surgery Liver Neoplasms - virology Male Middle Aged Multivariate Analysis Neoplasm Recurrence, Local - prevention & control Neoplasm Recurrence, Local - virology Proportional Hazards Models Retrospective Studies Risk Assessment Risk Factors Serum Albumin - metabolism Serum Albumin, Human Time Factors Treatment Outcome Tumor Burden |
| title | The Effect of Long-term Supplementation With Branched-chain Amino Acid Granules in Patients With Hepatitis C Virus-related Hepatocellular Carcinoma After Radiofrequency Thermal Ablation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A49%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Effect%20of%20Long-term%20Supplementation%20With%20Branched-chain%20Amino%20Acid%20Granules%20in%20Patients%20With%20Hepatitis%20C%20Virus-related%20Hepatocellular%20Carcinoma%20After%20Radiofrequency%20Thermal%20Ablation&rft.jtitle=Journal%20of%20clinical%20gastroenterology&rft.au=Nishikawa,%20Hiroki&rft.date=2013-04&rft.volume=47&rft.issue=4&rft.spage=359&rft.epage=366&rft.pages=359-366&rft.issn=0192-0790&rft.eissn=1539-2031&rft_id=info:doi/10.1097/MCG.0b013e31826be9ad&rft_dat=%3Cproquest_cross%3E1316377115%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1316377115&rft_id=info:pmid/23090049&rfr_iscdi=true |